The American Journal of Managed Care1h
Positive OS for Bladder Cancer Combo, Biomarkers on Tap at ASCO GU 2025
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase ...
oncnursingnews2h
Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer
Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...
Armed robbery in Revesby4h
Pfizer, Astellas' PADCEV Plus KEYTRUDA Shows Efficacy
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...
Targeted Oncology7h
Seeking Optimal Combinations and Treatment Sequencing in Cervical Cancer
Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...
The American Journal of Managed Care7h
Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
Pfizer and Astellas report improved survival in bladder cancer trial
NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...
Pfizer and Astellas announce results from phase 3 EV-302 clinical trial
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...